Full TitleMAGNETISMM-3 An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants with Multiple Myeloma who are Refractory to At Least One Proteasome Inhibitor, One Immunomodulatory Drug and One Anti-CD38 Antibody
The purpose of this study is to assess the safety and effectiveness of the investigational treatment PF-06863135 for patients with multiple myeloma that has come back or continues to grow despite treatment. PF-06863135 is type of drug called a bispecific antibody, which is designed to bind to two different proteins at the same time. One is a protein on myeloma cells and the other protein is on the surface of immune cells called T cells. Researchers think that PF-06863135 may activate T cells to target and destroy multiple myeloma cells. PF-06863135 is given as an injection under the skin of the abdomen or thigh.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have multiple myeloma that has come back or continues to grow despite prior treatment that included at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody.
- Patients should recover from the serious side effects of previous treatments before entering the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alexander Lesokhin at 212-639-3069.